Compare VABK & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VABK | MIST |
|---|---|---|
| Founded | 1998 | 2003 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 215.8M | 176.3M |
| IPO Year | 2013 | 2019 |
| Metric | VABK | MIST |
|---|---|---|
| Price | $40.57 | $1.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 4.6K | ★ 1.9M |
| Earning Date | 04-30-2026 | 02-22-2026 |
| Dividend Yield | ★ 3.58% | N/A |
| EPS Growth | N/A | ★ 51.80 |
| EPS | ★ 2.45 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.42 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $34.56 | $0.63 |
| 52 Week High | $44.50 | $3.06 |
| Indicator | VABK | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 46.27 | 33.58 |
| Support Level | $39.78 | $1.70 |
| Resistance Level | $43.34 | $1.89 |
| Average True Range (ATR) | 1.06 | 0.09 |
| MACD | -0.20 | -0.01 |
| Stochastic Oscillator | 10.93 | 3.47 |
Virginia National Bankshares Corp is a bank holding company which is engaged in the commercial and retail banking business. The bank offers a range of banking and related financial services, including checking accounts, negotiable order of withdrawal accounts, money market deposit accounts, certificates of deposit, individual retirement accounts and other depository services. Its segments include the Bank, VNB Trust and Estate Services, Sturman Wealth Advisors, and Masonry Capital. The Bank's commercial banking activities involve making loans, taking deposits and offering related services to individuals, businesses, and charitable organizations.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).